In addition to the 100% recognition of the amount required by Diapath as funding, the European community has also made available to participate in the equity of Diapath with 5 million euro, as required by the blanded financing formula, where the potential regarding both project and company are particularly innovative.
During the preliminary step concerning the evaluation of the different financial opportunities promoted by the European Commission, Diapath has been supported by Confindustria Bergamo and Confindustria Lombardia.
Founded in 1997, Diapath moves its first step as distributor of reagents and medical instruments regarding Anatomic Pathology. In few years Diapath has changed, becoming an international brand leading the research and creating high-tech instrument highly appreciated by hospitals and private clinics thanks also to the new management arrangement including Vladimiro Bergamini as CEO, the COO Alberto Battistel, and a team of experts composed by Carmelo Lupo as Head of Innovation, Federica Bergamini as Marketing & Customer Service Manager, Paolo Danzi as Operations and Lean Management and Alessandra Bergamini as Export Area Manager.
Diapath Vision is to become the most innovative Brand worldwide for Anatomic Pathology investing each year more than the 8% of the revenue in Research & Development.